Clinical Trial: Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286747) titled 'Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)' on Dec. 03.

Brief Summary: The goal of this clinical trial is to prevent the change from prediabetes (a pre-stage of type 2 diabetes mellitus (T2DM)) to T2DM in participants with prediabetes using oral CIR-NA (a nicotinic acid formulation that is designed to be released after reaching the ileum) which targeted the gut microbiota. The main questions it aims to answer are:

1. Is CIR-NA effective and does it prevent the change from prediabetes to T2DM?

2. Is the safety of CIR-NA that was observed in the Phase I clinical...